RxDoctor Payments Data

Hymie Faitelson, MD

Clinical Cardiac Electrophysiology · Tucson, AZNPI 1912962804

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $7,018 of the $11,596 with a category attached, or 60.5%. 25 manufacturers reported payments, led by Medtronic at 59.6% of the total. Reporting peaked in 2019 at $7,272 and has fallen 93.0% since, to $508 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in AZ, where the typical reported total is $29,180.

$11,596in general payments, 2019–2025

Across 192 payments — averaging $60.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$7K
  • Boston Scientific$1K
  • Abiomed$787
  • Abbott$768
  • Cvrx, Inc.$289
  • Novartis$233
  • plus $1K from 19 others

What the payments were for

  • Travel & lodging$7,01861%
  • Food & beverage$4,48739%
  • Education$911%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,596 in reported general payments places this provider in the 25th percentile of 80 clinical cardiac electrophysiology providers in Arizona.

See all clinical cardiac electrophysiology providers in Arizona

Medicare billing

Part B allowed, 2024
$361,747
Medicare patients
874
Services billed
4,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban287$338,820
XareltoRivaroxaban84$106,574
EntrestoSacubitril/Valsartan47$57,798
MultaqDronedarone Hcl30$35,563
Repatha SureclickEvolocumab14$18,425
OzempicSemaglutide15$15,454
JardianceEmpagliflozin14$13,960
FarxigaDapagliflozin Propanediol15$12,034
BrilintaTicagrelor11$10,310
EdarbiAzilsartan Medoxomil13$9,478
Flecainide Acetate181$7,083
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$6,697
Nebivolol Hcl47$4,080
Amiodarone Hcl160$4,070
Metoprolol Succinate290$3,560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$61$338,820287 claims
Johnson & JohnsonXarelto$30$106,57484 claims
NovartisEntresto$233$57,79847 claims
Sanofi-aventis U.S. LLCMultaq$59$35,56330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 80 clinical cardiac electrophysiology providers in Arizona.

Other clinical cardiac electrophysiology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →